Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Acquired Rep. Gilbert Ray Cisneros, Jr.

Key Points

• Representative Gilbert Ray Cisneros, Jr. purchased shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) worth between $1,001 and $15,000, as disclosed on September 12th.
• Ultragenyx Pharmaceutical's stock has recently shown positive performance, trading at $29.48 with a market capitalization of $2.84 billion and reporting a 13.2% revenue increase compared to the same quarter last year.
• Recent insider transactions include an executive selling shares at an average price of $31.17, indicating a 3.24% reduction in ownership, while institutional investors have increased their stakes significantly in the company.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). In a filing disclosed on September 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Ultragenyx Pharmaceutical stock on August 8th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Semtech NASDAQ: SMTC on 9/2/2025.
• Sold $1,001 - $15,000 in shares of Chart Industries NYSE: GTLS on 9/2/2025.
• Purchased $1,001 - $15,000 in shares of Avient NYSE: AVNT on 9/2/2025.
• Sold $1,001 - $15,000 in shares of Amdocs NASDAQ: DOX on 8/27/2025.
• Sold $1,001 - $15,000 in shares of Amdocs NASDAQ: DOX on 8/26/2025.
• Purchased $1,001 - $15,000 in shares of Intapp NASDAQ: INTA on 8/26/2025.
• Purchased $1,001 - $15,000 in shares of APi Group NYSE: APG on 8/26/2025.
• Purchased $1,001 - $15,000 in shares of Waters NYSE: WAT on 8/26/2025.
• Purchased $1,001 - $15,000 in shares of Semtech NASDAQ: SMTC on 8/26/2025.
• Sold $1,001 - $15,000 in shares of Fortive NYSE: FTV on 8/26/2025.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ RARE traded down $0.98 during trading on Friday, hitting $28.13. The stock had a trading volume of 3,627,110 shares, compared to its average volume of 1,390,204. The stock has a 50 day simple moving average of $28.97 and a 200 day simple moving average of $33.97. Ultragenyx Pharmaceutical Inc. has a one year low of $25.81 and a one year high of $59.50. The stock has a market capitalization of $2.71 billion, a price-to-earnings ratio of -5.09 and a beta of 0.21.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.27) by $0.10. The business had revenue of $166.50 million for the quarter, compared to analyst estimates of $161.37 million. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The business's revenue for the quarter was up 13.2% on a year-over-year basis. During the same period in the previous year, the company earned ($1.52) earnings per share. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Insider Buying and Selling

In other news, EVP Karah Herdman Parschauer sold 2,450 shares of the firm's stock in a transaction on Friday, September 12th. The shares were sold at an average price of $31.17, for a total value of $76,366.50. Following the sale, the executive vice president owned 73,271 shares in the company, valued at approximately $2,283,857.07. This trade represents a 3.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 5.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Guggenheim reaffirmed a "buy" rating and set a $64.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 20th. Wells Fargo & Company decreased their price objective on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating on the stock in a report on Thursday, July 10th. Cantor Fitzgerald reiterated an "overweight" rating and set a $105.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, September 5th. HC Wainwright restated a "buy" rating and issued a $80.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Tuesday, September 9th. Finally, Morgan Stanley reduced their price objective on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating on the stock in a report on Monday, July 14th. Eleven equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $81.50.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. California State Teachers Retirement System boosted its holdings in shares of Ultragenyx Pharmaceutical by 0.3% in the fourth quarter. California State Teachers Retirement System now owns 78,051 shares of the biopharmaceutical company's stock worth $3,284,000 after buying an additional 268 shares during the period. GAMMA Investing LLC raised its position in Ultragenyx Pharmaceutical by 76.2% during the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 323 shares in the last quarter. Xponance Inc. raised its position in Ultragenyx Pharmaceutical by 2.8% during the first quarter. Xponance Inc. now owns 12,552 shares of the biopharmaceutical company's stock valued at $455,000 after acquiring an additional 347 shares in the last quarter. Oak Ridge Investments LLC raised its position in Ultragenyx Pharmaceutical by 2.3% during the first quarter. Oak Ridge Investments LLC now owns 17,757 shares of the biopharmaceutical company's stock valued at $643,000 after acquiring an additional 395 shares in the last quarter. Finally, Teacher Retirement System of Texas raised its position in Ultragenyx Pharmaceutical by 1.8% during the second quarter. Teacher Retirement System of Texas now owns 22,773 shares of the biopharmaceutical company's stock valued at $828,000 after acquiring an additional 404 shares in the last quarter. Institutional investors own 97.67% of the company's stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.